PTO/SB/08 (09-06)
Approved for use through 03/31/2007. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Date Submitted: November 20, 2007

(use as many sheets as necessary)

Sheet | 1 | of | 1

Complete if Known	
Application Number	10/530,262
Filing Date	10/6/2003
First Named Inventor	Masahiko KOIKE
Art Unit	1618
Examiner Name	Micah Paul Young
Attorney Docket Number	084437-0172

OIPE IAP97 NOV 20 2007 PATENT & TRADEMARK OFFICE

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Document Number Number-Kind Code[2] (*if known*)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Foreign Patent Document Country Code[3]-Number[4]-Kind Code[5] (*if known*)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Documents	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T[6]
/R.W./	D1	EP 1 329 217 A1	07/23/2003	Takeda Chemical Ind., Ltd.		
	D2	WO 99/03477 A1	01/28/1999	Smithkline Beecham P.L.C.		
	D3	WO 00/66102 A2	11/09/2000	City of Hope		
	D4	WO 01/32158 A2	05/10/2001	Bristol-Myers Squibb Co.		

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.[1]	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T[6]
	D5	CHILCOTT et al., "A Systematic Review of the Clinical Effectiveness of Pioglitazone in the Treatment of Type 2 Diabetes Mellitus," Clinical Therapeutics, 2001, 23(11):1792-1823.	
	D6	EINHORN et al., "Pioglitazone Hydrochloride in Combination with Metformin in the Treatment of Type 2 Diabeter Mellitus: A Randomized, Placebo-Controlled Study," Clinical Therapeutics, 2000, 22(12):1395-1409.	

Examiner Signature	/Rachael Welter/	Date Considered	04/30/2008

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /R.W./